JP2019525903A5 - - Google Patents

Download PDF

Info

Publication number
JP2019525903A5
JP2019525903A5 JP2018566415A JP2018566415A JP2019525903A5 JP 2019525903 A5 JP2019525903 A5 JP 2019525903A5 JP 2018566415 A JP2018566415 A JP 2018566415A JP 2018566415 A JP2018566415 A JP 2018566415A JP 2019525903 A5 JP2019525903 A5 JP 2019525903A5
Authority
JP
Japan
Prior art keywords
composition
inhibitor
c14orf142
tmem229b
kif3b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018566415A
Other languages
English (en)
Japanese (ja)
Other versions
JP7306829B2 (ja
JPWO2017214726A5 (https=
JP2019525903A (ja
Filing date
Publication date
Priority claimed from CA2932910A external-priority patent/CA2932910A1/en
Application filed filed Critical
Publication of JP2019525903A publication Critical patent/JP2019525903A/ja
Publication of JPWO2017214726A5 publication Critical patent/JPWO2017214726A5/ja
Publication of JP2019525903A5 publication Critical patent/JP2019525903A5/ja
Priority to JP2023107289A priority Critical patent/JP2023123748A/ja
Application granted granted Critical
Publication of JP7306829B2 publication Critical patent/JP7306829B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018566415A 2016-06-14 2017-06-14 転移性癌の診断及び治療の方法 Active JP7306829B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023107289A JP2023123748A (ja) 2016-06-14 2023-06-29 転移性癌の診断及び治療の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2932910A CA2932910A1 (en) 2016-06-14 2016-06-14 Methods for diagnosing and treating metastatic cancer
CA2,932,910 2016-06-14
PCT/CA2017/050729 WO2017214726A1 (en) 2016-06-14 2017-06-14 Methods for diagnosing and treating metastatic cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023107289A Division JP2023123748A (ja) 2016-06-14 2023-06-29 転移性癌の診断及び治療の方法

Publications (4)

Publication Number Publication Date
JP2019525903A JP2019525903A (ja) 2019-09-12
JPWO2017214726A5 JPWO2017214726A5 (https=) 2023-06-02
JP2019525903A5 true JP2019525903A5 (https=) 2023-06-02
JP7306829B2 JP7306829B2 (ja) 2023-07-11

Family

ID=60655897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018566415A Active JP7306829B2 (ja) 2016-06-14 2017-06-14 転移性癌の診断及び治療の方法
JP2023107289A Pending JP2023123748A (ja) 2016-06-14 2023-06-29 転移性癌の診断及び治療の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023107289A Pending JP2023123748A (ja) 2016-06-14 2023-06-29 転移性癌の診断及び治療の方法

Country Status (8)

Country Link
US (2) US11236331B2 (https=)
EP (1) EP3468564A4 (https=)
JP (2) JP7306829B2 (https=)
CN (1) CN109562121A (https=)
AU (2) AU2017285726B2 (https=)
CA (2) CA2932910A1 (https=)
MX (2) MX2018015474A (https=)
WO (1) WO2017214726A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11304988B2 (en) * 2018-01-24 2022-04-19 Northwestern University Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (KLC1C)
US20210251963A1 (en) * 2018-09-06 2021-08-19 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
CN117187375B (zh) * 2023-09-12 2024-06-18 上海谱希和光基因科技有限公司 Kdelr3生物标志物在诊断高度近视中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6040166A (en) 1985-03-28 2000-03-21 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences, including a probe
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE3938907C2 (de) 1989-11-24 1999-11-04 Dade Behring Marburg Gmbh Mittel zum Lagern und Suspendieren von Zellen, insbesondere Erythrozyten
FR2814349B1 (fr) 2000-09-27 2002-12-06 Salomon Sa Sac a dos
KR101446626B1 (ko) 2005-09-02 2014-10-06 도레이 카부시키가이샤 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법
CN101300348A (zh) 2005-09-02 2008-11-05 东丽株式会社 肾癌诊断、肾癌患者预后预测用的组合物及方法
WO2007056604A2 (en) 2005-11-09 2007-05-18 Irm Llc Methods and compositions for modulating cell motility and inhibiting tumor metastasis
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2013098797A2 (en) * 2011-12-31 2013-07-04 Kuriakose Moni Abraham Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
US20160025728A1 (en) 2013-03-15 2016-01-28 Board Of Regents, The University Of Texas System Brain-specific gene signature of tumor cells
JP6663149B2 (ja) 2014-07-04 2020-03-11 国立大学法人高知大学 膵がん細胞浸潤転移阻害剤

Similar Documents

Publication Publication Date Title
Xing et al. lncRNA directs cooperative epigenetic regulation downstream of chemokine signals
Al-Khanbashi et al. Tissue and serum miRNA profile in locally advanced breast cancer (LABC) in response to neo-adjuvant chemotherapy (NAC) treatment
WO2006024283A3 (de) Verbindungen und methoden zur behandlung, diagnose und prognose bei pankreaserkrankungen
JP2009502115A5 (https=)
JP2012135301A5 (https=)
US20240076677A1 (en) TOXIC RNAi ACTIVE SEED SEQUENCES FOR KILLING CANCER CELLS
JP2010508042A5 (https=)
MX2010002113A (es) Metodos para detectar oligonucleotidos.
WO2014205555A1 (en) Methods and uses for diagnosis and treatment of prostate cancer
JP2008532477A5 (https=)
JP2014527807A5 (https=)
Koppen et al. Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma
JP2012501164A5 (https=)
WO2011056073A3 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds
NO20092965L (no) Sammensetninger og fremgangsmater for a forhindre kreft med cupredoksiner
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
JP2019525903A5 (https=)
WO2007085497A8 (en) Markers for the prediction of outcome of anthracycline treatment
Song et al. Clinical manifestations and epigenetic mechanisms of gastric mucosa associated lymphoid tissue lymphoma and long-term follow-up following Helicobacter pylori eradication
JP2016506412A5 (https=)
KR20180040107A (ko) Rna 간섭 유도 핵산 및 이를 포함하는 hpv 감염 유발 암의 치료용 약학 조성물
JP2005511023A5 (https=)
Yu et al. RETRACTED ARTICLE: LINC00504 Promotes the Malignant Biological Behavior of Breast Cancer Cells by Upregulating HMGB3 via Decoying MicroRNA-876-3p
CN115666590A (zh) 口腔鳞癌相关生物标志物及诊断和治疗方法
RU2011111551A (ru) C12orf48 как ген-мишень для лечения и диагностики рака